FOLFOX6联合复方斑蝥胶囊治疗晚期原发性肝癌的效果  

Efficacy of FOLFOX6 regimen combined with Fufangbanmao capsules for advanced primary hepatocarcinoma treatment

作　　者：王夏飞[1] 王贵吉[1] 裴迎新[2] 李向垒[1] 张琪[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052 [2]郑州大学公共卫生学院营养与食品卫生学教研室,郑州450001

出　　处：《郑州大学学报（医学版）》2012年第3期385-387,共3页Journal of Zhengzhou University(Medical Sciences)

摘　　要：目的:观察FOLFOX6方案联合复方斑蝥胶囊治疗晚期原发性肝癌的疗效。方法:收集晚期原发性肝癌55例,分别应用FOLFOX6方案(31例)和FOLFOX6联合复方斑蝥胶囊方案(24例)治疗。结果:FOLFOX6组和联合组的有效率分别为12.9%和16.7%,疾病控制率分别是48.4%和54.2%,但差异均无统计学意义(χ2<0.001,χ2=0.181,P>0.05)。联合组中位肿瘤进展时间7.4个月,长于FOLFOX6组的4.9个月(Z=2.220,P=0.026)。联合组KPS改善率为74.2%,高于FOLFOX6组的51.6%(χ2=4.428,P=0.035)。联合组不良反应中粒细胞减少和贫血发生率低于FOLFOX6组(χ2=7.913和4.045,P<0.05)。结论:FOLFOX6联合复方斑蝥胶囊方案治疗晚期原发性肝癌能改善患者生活质量,降低粒细胞减少和贫血的发生。Aim：To evaluate the efficacy of FOLFOX6 regimen combined with Fufangbanmao capsules for advanced primary hepatocarcinoma treatment.Methods：Fifty five untreated patients with advanced primary hepatocarcinoma were collected,among whom,31 were treated with FOLFOX6 regimen,24 were treated with FOLFOX6 combined with Fufangbanmao capsules.Results：The total response rates（RR） of the FOLFOX6 group and combination group were 12.9% and 16.7%,and disease control rate（DCR） were 48.4% and 54.2%,respectively.No significant differences were found in RR and DCR between the two groups（χ20.001,χ2=0.181,P0.05）.Media TTP was 4.9 months in FOLFOX6 group,shorter than that（7.4 months） in combination group（Z=2.220,P=0.026）;improvement rate of KPS scores was 51.6% in FOLFOX6 group,lower than that（74.2%） in combination group（χ2=4.428,P=0.035）.Granulocytopenia and anemia incidences were significantly lower in combination group compared with those of FOLFOX6 group（χ2=7.913,4.045,P0.05）.Conclusion：The synergism of FOLFOX6 and Fufangbanmao capsules could improve quality of life,and reduce the incidence of granulocytopenia and anemia during the treatment of advanced primary hepatocarcinoma.

关 键 词：原发性肝癌 化学治疗 斑蝥 奥沙利铂 

分 类 号：R735.3[医药卫生—肿瘤]